SUNNYVALE, Calif., Sept. 17 /PRNewswire-FirstCall/ -- Cepheid will present at the UBS Global Life Sciences Conference on September 26, 2007 at 12 p.m. ET at the Grand Hyatt New York. Cepheid’s Chief Financial Officer John R. Sluis and Chief Medical and Technology Officer Dr. David Persing will provide a corporate overview.
The webcast, along with accompanying presentation slides, may be accessed on Cepheid’s Web site at http://www.cepheid.com under Investors: Events: Webcasts and Presentations. A replay of the webcast presentation will be available for 90 days.
About Cepheid
Cepheid , based in Sunnyvale, California, is a molecular diagnostics company that develops, manufactures, and markets fully-integrated systems for genetic analysis in the clinical, industrial and biothreat markets. The company’s systems enable rapid, sophisticated genetic testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The company’s easy-to-use systems integrate a number of complicated and time-intensive steps, including sample preparation, DNA amplification and detection, which enable the analysis of complex biological samples in its proprietary test cartridges. Through its strong molecular biology capabilities, the company is focusing on those applications where rapid molecular testing is particularly important, such as identifying infectious disease and cancer in the clinical market; food, agricultural, and environmental testing in the industrial market; and identifying bio-terrorism agents in the biothreat market. See http://www.cepheid.com for more information.
Cepheid
CONTACT: John L. Bishop, CEO, john.bishop@cepheid.com, or John R. Sluis,CFO, john.sluis@cepheid.com, both of Cepheid, +1-408-541-4191; or Media,Chris Stamm of Schwartz Communications, +1-781-684-0770,cepheid@schwartz-pr.com, for Cepheid; or Investors, Jason Spark of PorterNovelli Life Sciences, +1-619-849-6005, jspark@pnlifesciences.com, forCepheid
Web site: http://www.cepheid.com/
